both age and sex was significant (x2= 10 7, df= 1, p 0001). This excess in controls over diabetics of more than three to two was roughly constant at all ages and in both sexes. 
Comment
This study showed that, of patients attending outpatient clinics, those with diabetes suffered significantly less from migraine than those without diabetes. The explanation for this finding was not clear but it may have been associated with an underlying anomaly of carbohydrate metabolism that may exist in patients with migraine. Hockaday has suggested that the central response to absolute or relative shortage of carbohydrate supply might be abnormal in some patients with migraine and that this could lead to a neurogenically determined attack.4 Further biochemical investigation of patients with both migraine and diabetes may lead to a better understanding of the influence that blood glucose concentrations have on the genesis of a migraine attack.
We thank Professor B E Clayton (University of Southampton) for her encouragement and help in preparing the report; and Dr H Platt (Basingstoke) and Dr Y Todd (Southampton) for their cooperation. intranasally, however, may stimulate rises of luteinising hormone and in some cases testosterone concentrations in the period after drug administration, even after many months of treatment,4 which precludes this type of administration over long periods. The likely mechanism of this intermittent stimulation of luteinising hormone and testosterone release is phasic peaks of peptide which result from an intermittent bolus administration of these analogues. Possibly a depot formulation in which drug is continuously available would overcome this problem. We report preliminary endocrine studies of a depot preparation of one such analogue, Zoladex (ICI 118630), which is administered subcutaneously every 28 days.
Patients, methods, and results
We studied eight patients with newly diagnosed advanced metastatic prostatic cancer who had not previously received any form of endocrine treatment. The depot preparation, which consists of 3-6 mg of the luteinising hormone releasing hormone analogue bound to a biodegradable lactide and glycolide polymer,5 was given by subcutaneous injection into the anterior abdominal wall every 28 days. Endocrine assessment of serum testosterone and luteinising hormone concentrations was performed at intervals throughout the study. A 24 hour profile 15 days after the sixth depot injection was also performed.
Serum luteinising hormone-The mean serum luteinising hormone concentration rose to twice the basal value within two hours of the first depot injection, and continued to rise to a maximum at 48 hours (figure). Down regulation to predose values occurred by day 8, and full suppression by 21 days. Twenty four hour profiles of luteinising hormone studied after the sixth depot injection showed no change in values, which remained fully suppressed throughout the period of study.
Serum testosterone-Seven of the eight patients had a serum testosterone concentration within the normal range at the beginning of the study. In one patient the value was in the castrate range and remained so throughout. In the other seven patients maximum stimulation occurred by day 4, and down regulation to basal values by day 8 ( figure) . Subcastrate values of testosterone-that is, less than 3 nmol/l (0 9 ng/ml)-were achieved by day 15 in all patients. Testosterone remained at that value throughout the period of study. Apart from mild discomfort lasting less than half an hour, no symptoms at the site of injection were reported by any patient. No worsening of symptoms was seen in any patient during the initial gonadotrophin stimulatory phase. At six months no patient showed signs of progression of disease. Three had a greater than 50°' reduction in size of the prostate, and acid phosphatase activity returned to normal in those in whom it had been raised.
Comment
The discovery that superactive luteinising hormone releasing hormone analogues lower testosterone values to a greater degree than stilboestrol and that they are at least as effective in the treatment of prostatic cancer has revolutionised care of this condition.
Down regulation of receptors depends on maintaining a continuously raised agonist concentration. While daily administration of high concentrations of the superactive agonist luteinising hormone releasing hormone analogue is capable of maintaining activity for prolonged periods, the fluctuation of blood concentrations may be the reason why rises in testosterone are sometimes seen during long term administration. Indeed, it is recognised with other peptide systems that maintaining a constant plasma concentration is critical in producing down regulation (unpublished observation). Thus there is every reason to suppose that a constant availability such as is produced by depot administration is likely to be more effective in maintaining the down regulation.
The regulatory peptide control system in the body has been relatively recently discovered but it is clear that it is highly complex and has an important role in the control of every organ system. Pharmaceutical intervention in the regulatory peptide system therefore offers considerable therapeutic potential. This has already been exploited with such agents as captopril, preventing the production of an active peptide, and naloxone, blocking the natural peptide receptor. It has not been possible, hitherto, to contemplate long term administration of peptide as treatment except in extreme circumstances, such as diabetes mellitus, where a poor drug delivery system is tolerable only in the face of a dire alternative. The availability of a safe, effective long term depot, which is capable of fulfilling this role, may therefore have a wide application, particularly as other superagonist regulatory peptides are developed. 
Urinoma complicating papillary necrosis in diabetes
The term urinoma describes an encapsulated collection of urine that has extravasated from the upper renal tract. We describe a case in which a urinoma formed secondary to ureteric obstruction caused by a sloughed papilla.
Case report
A 76 year old woman with maturity onset diabetes normally controlled by diet presented with left sided abdominal pain, polydipsia, polyuria, and confusion of one week's duration. She was severely dehydrated with tenderness in the left flank. On admission her blood glucose concentration was 39 mmol/l (703 mg/100 ml) with no evidence of metabolic acidosis or hypernatraemia. The white cell count was 20-8 x 109/1 with 83% neutrophils.
Blood and urine cultures were sterile despite the lack of previous antibiotic treatment. She rapidly improved after administration of insulin and intravenous fluids, but the abdominal pain persisted.
Abdominal ultrasound ( figure) showed the presence of a transonic mass adjacent to the lower pole of the left kidney, and high dose (100 ml Conray 325) intravenous urography confirmed the presence of an extrinsic mass causing lateral displacement of the kidney. The left collecting system was slightly distended and contained several lucent filling defects, particularly in the upper group of calices. The right kidney was normal. The findings on intravenous urography were consistent with unilateral papillary necrosis.
The transonic mass was aspirated percutaneously under ultrasound control, producing 150 ml straw coloured sterile fluid with 3850 white cells/I and a urea concentration of 17-6 mmol/l (106 mg/100 ml). On the -~~~~~Ski surfac Left -~renal rinm Pelvis
Prone sagittal ultrasound scan to left of midline same day the plasma urea concentration was 4-9 mmol/I (29 mg/100 ml), confirming that this fluid was indeed urine. One week later a second ultrasound examination showed that the mass had resolved, and amorphous debris was noted in the bladder. Microscopy of this showed white cells and epithelial cells but no recognisable papillary material.
Comment
Most urinomas described elsewhere resulted from accidental or surgical trauma,' but spontaneous cases have been described secondary to ureteric obstruction with calculi,' bladder and ureteric tumours,3 and bladder outlet obstruction. 4 In this case there was evidence of papillary necrosis, urinary obstruction, and urinoma. We believe that the urinoma was secondary to transient ureteric obstruction by a sloughed papilla. One other case of urinoma in a diabetic with papillary necrosis has been reported, but a ureteric calculus was also identified. 5 We therefore conclude that urinoma may be a rare complication of papillary necrosis.
